MDxHealth SA Overview
Pro stress-test →MDxHealth SA is a commercial-stage precision diagnostics company that provides urologic solutions in the United States, Europe, and internationally. The company's tests are based on proprietary genetic, epigenetic and other molecular technologies that assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to specific therapies.
Strategic Profile
Pro stress-test →Headquartered in Belgium with significant U.S. operations, the company has successfully transitioned into a commercial-stage powerhouse focused on urologic cancers. MDxHealth signed a definitive agreement to acquire the business of Exosome Diagnostics, Inc. for $15 million (August 2025), with $5 million in stock at closing and $2.5 million annually over the following 4 years, and completed the acquisition on September 15, 2025.
Competitive Landscape
Pro stress-test →Comparable companies in the precision diagnostics and molecular diagnostics space include Precipio (PRPO), Interpace Biosciences (IDXG), CareDx (CDNA), NeoGenomics (NEO), Myriad Genetics (MYGN), Personalis (PSNL), and Labcorp Holdings (LH). MDxHealth differentiates through specialized focus on urologic cancer diagnostics with proprietary epigenetic and molecular testing platforms.
Industry Context
MDxHealth SA operates in Precision Diagnostics / Molecular Diagnostics.
Key facts
Founded: 2003 · Headquarters: Herstal, Belgium · Employees: 312 · Revenue: $108M-$110M (2025 guidance) · Market cap: $39.5M